17977-76-3

Usage

Uses

Used in Pharmaceutical Industry:
2-chloro-N-(4-chloro-2-((hydroxyiMino)(phenyl)Methyl)phenyl)acetaMide is used as an intermediate in the synthesis of quinazoline (Q670100) and 1,4-diazepine derivatives. These compounds are of significant interest in the pharmaceutical industry due to their diverse range of biological activities, including anticancer, antiviral, and anti-inflammatory properties. The development of new and effective drugs based on these scaffolds can potentially lead to the discovery of novel therapeutic agents for the treatment of various diseases.
Used in Antioxidant Activity:
2-chloro-N-(4-chloro-2-((hydroxyiMino)(phenyl)Methyl)phenyl)acetaMide also exhibits antioxidant activity, which is an important property in the field of health and nutrition. Antioxidants are compounds that can neutralize free radicals, which are unstable molecules that can cause damage to cells and contribute to the aging process and the development of various diseases. By incorporating 2-chloro-N-(4-chloro-2-((hydroxyiMino)(phenyl)Methyl)phenyl)acetaMide into food products, cosmetics, or pharmaceutical formulations, it can help protect against oxidative stress and promote overall health and well-being.

Upstream product

• 719-59-5 5-chloro-2-aminobenzophenone 
• 79-04-9 chloroacetyl chloride 
• 18097-52-4 2-amino-5-chlorobenzophenone oxime 

Downstream Products

• 604-75-1 oxazepam 
• 84044-34-8 7-Chloro-5-phenyl-3-(3',5'-dimethyl-1'-pyrazolyl)-2,3-dihydro-1H-1,4-benzodiazepin-2-one 
• 72624-56-7 3-(benzyl-methyl-amino)-7-chloro-5-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one 
• 72624-55-6 7-chloro-3-(N-methylanilino)-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 
• 27723-30-4 3-ethylamino-7-chloro-5-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one 
• 5358-44-1 3,7-dichloro-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepine-2-one 

Relevant academic research and scientific papers

Synthesis of substituted 3-anilino-5-phenyl-1,3-dihydro-2H-1,4- benzodiazepine-2-ones and their evaluation as cholecystokinin-ligands

3-Amino-1,4-benzodiazepines as well as chemically related diverse amines were prepared from oxazepam and subsequently screened on the cholecystokinin receptor in a radiolabel binding assay. Oxazepam 2 was activated via its 3-chloro-1,4-benzodiazepine intermediate 3 and was reacted with a large series of aliphatic and aromatic amines. The substituted 3-anilino-1,4-benzodiazepine structure was identified as lead structure in a diverse series of 3-amino-1,4-benzodiazepines 4-38 and the full SAR (structure-activity relationship) optimisation provided 3-anilinobenzodiazepines 16-38 with CCK 1 receptor selectivity to CCK2. The compounds 18, 24, 28 and 33 have shown affinities at the CCK1 receptor of 11, 10, 11 and 9 nM, respectively. These equipotent CCK1 ligands were fully evaluated in behaviour pharmacological essays. An antidepressant effect was identified in the tail suspension- and the Porsolt swimming-test. The ED50 values for 24 and 28 were determined in these assays as 0.46 and 0.49 mg/kg. The mixed antagonist 37 showed in addition to the antidepressant effects anxiolytic properties.

NOVEL 3-SUBSTITUTED-1,4-BENZODIAZEPINES

The present invention relates to compounds of formula (I). The invention also relates to methods for preparing the compounds and their uses as CCK receptor ligands and CCK antagonists.